Form 4: Recursion Pharmaceuticals: Director Borgeson Trades Shares

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported a transaction involving Class A Common Stock under a Rule 10b5-1 trading plan.

Summary

• Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc. (RXRX), executed a transaction on May 5, 2026.
• The transaction involved the disposal of 30,000 shares of Class A Common Stock at a price of $3.52 per share.
• This sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on August 31, 2025.
• Following this transaction, Borgeson beneficially owns 6,199,863 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction executed under a pre-defined plan, without immediate implications for the company's operational or financial performance.

Negatives

• Director Blake Borgeson sold 30,000 shares of Class A Common Stock.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a pre-arranged trading strategy, often employed by executives to diversify holdings or manage personal finances without appearing to trade on material non-public information.

Stakeholder Impact

• Shareholders: The sale by a director may be perceived by some investors as a negative signal, although the use of a Rule 10b5-1 plan mitigates concerns about insider trading based on material non-public information.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Recursion Pharmaceuticals, RXRX, Blake Borgeson, Class A Common Stock, Beneficial Ownership